Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jemperli is a prescription programmed death receptor-1 blocking antibody containing dostarlimab. Current labeling includes primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel, selected mismatch repair deficient recurrent or advanced endometrial cancer as monotherapy, and selected dMMR recurrent or advanced solid tumors.
read more about jemperli ...Dostarlimab binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. This reduces inhibitory signaling to T cells and increases immune activity against susceptible tumor cells.
Jemperli is used in adults with primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel followed by Jemperli alone. Monotherapy is used for selected dMMR recurrent or advanced endometrial cancer and selected dMMR recurrent or advanced solid tumors after prior treatment under current labeling.
For primary advanced or recurrent endometrial cancer, Jemperli is given as 500 mg by intravenous infusion every three weeks for six cycles with carboplatin and paclitaxel, followed by 1000 mg every six weeks. Monotherapy regimens use 500 mg every three weeks for four cycles followed by 1000 mg every six weeks. Each infusion is given over 30 minutes.
Jemperli can cause severe or fatal immune-mediated reactions affecting organs including the lungs, colon, liver, endocrine glands, kidneys, skin, heart, and nervous system. Other serious concerns include infusion reactions, complications after allogeneic stem cell transplantation, and fetal harm. Severe toxicity can require treatment interruption or permanent discontinuation.
Current labeling includes primary advanced or recurrent endometrial cancer and selected mismatch repair deficient recurrent or advanced cancers.
Jemperli is given by intravenous infusion over 30 minutes.
Monotherapy uses 500 mg every three weeks for four cycles followed by 1000 mg every six weeks.
Yes. Immune-mediated reactions can affect several organs and can become severe or fatal.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. https://pubmed.ncbi.nlm.nih.gov/36972026/. Date Accessed October 6, 2026.
Dostarlimab-gxly Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a621030.html. Date Accessed October 6, 2026.
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly With Chemotherapy. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy. Date Accessed October 6, 2026.
JEMPERLI (Dostarlimab-gxly) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5. Date Accessed October 6, 2026.
Safety and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients With Advanced or Recurrent Endometrial Cancer: Interim Results From GARNET. https://pubmed.ncbi.nlm.nih.gov/35064011/. Date Accessed October 6, 2026.